Use of GLP-1 analogues needs great caution

BMJ

Volumn 342, Issue 7797, 2011, Pages 563-

  Yudkin, John S ^a   Lehman, Richard ^b   Krumholz, Harlan M ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; LIRAGLUTIDE; ROSIGLITAZONE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN;

BLINDNESS; COST BENEFIT ANALYSIS; DRUG COST; DRUG SAFETY; HUMAN; KIDNEY FAILURE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VASCULAR DISEASE; DIABETIC ANGIOPATHY; METABOLISM;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 79955049820     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d1478     Document Type: Letter

References (3)

1. Wilding JPH, Hardy K. Glucagon-like peptide-1 analogues for type 2 diabetes. BMJ 2011;342:d410. (16 February.)
2. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010;53:2079-85.
3. Lehman R, Yudkin JS, Krumholz HM. Licensing drugs for diabetes. BMJ 2010;341:c4805.